Evidence map›Paper›PMID 39195339›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Oncologic and Functional Outcomes of Salvage Robot-Assisted Radical Prostatectomy: Report of the First 10 Cases.

Takahiro Oshina, Yuta Yamada, Tetsuya Fujimura, Satoru Taguchi, Yoshiyuki Akiyama, Jun Kamei, Tomoyuki Kaneko, Taketo Kawai, Daisuke Obinata, Daisuke Yamada and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Takahiro OshinaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID 0009-0007-0433-3741
Yuta YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Tetsuya FujimuraDepartment of Urology, Jichi Medical University, Tochigi 329-0498, Japan.
Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID 0000-0002-1291-4294
Yoshiyuki AkiyamaDepartment of Urology, Shinshu University School of Medicine, Nagano 390-8621, Japan.
Jun KameiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Tomoyuki KanekoDepartment of Urology, Teikyo University School of Medicine, Tokyo 173-8606, Japan.ORCID 0000-0002-5762-7563
Taketo KawaiDepartment of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba 272-8501, Japan.
Daisuke ObinataDepartment of Urology, Nihon University Itabashi Hospital, Tokyo 173-8610, Japan.ORCID 0000-0002-8584-4506
Daisuke YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Hiroshi FukuharaDepartment of Urology, Kyorin University School of Medicine, Tokyo 181-0004, Japan.
Tohru NakagawaDepartment of Urology, Teikyo University School of Medicine, Tokyo 173-8606, Japan.ORCID 0000-0003-4041-7241
Satoru TakahashiDepartment of Urology, Nihon University Itabashi Hospital, Tokyo 173-8610, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSalvage robot-assisted radical prostatectomy (sRARP) after PSA failure in patients who underwent initial radiotherapy or focal therapy has rarely been reported in Japan. We aimed to report the oncologic and functional outcomes of the first 10 cases of sRARP.

methodsTen patients underwent sRARP after failing to respond to initial radiotherapy or focal therapy. Initial definitive treatment included volumetric modulated arc therapy, intensity-modulated radio therapy, stereotactic body radiotherapy, heavy-ion radiotherapy, low-dose-rate brachytherapy, and high-intensity focused ultrasound. We retrospectively investigated 10 cases on oncologic and functional outcomes of sRARP.

resultsThe median PSA level at sRARP, amount of blood loss, and console time were 2.17 ng/mL, 100 mL, and 136 min, respectively. Positive surgical margins were found in half of the cases. Median follow-up was 1.1 years. There were no 30-day major complications. No patients had erections after sRARP. Urinary continence and biochemical recurrence (BCR) rate were 40% and 30% at 1 year after sRARP, respectively.

conclusionsSalvage RARP may be a feasible option after PSA failure in patients who underwent radiotherapy or focal therapy as initial treatment, showing acceptable BCR rate.

Indexed as

ProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresSalvage TherapyAgedHumansMaleMiddle AgedProstate-Specific AntigenRetrospective StudiesTreatment OutcomeProstate-Specific Antigenfocal therapyprostatectomyradiotherapyrobot-assisted radical prostatectomysalvage radical prostatectomy

Identifiers

PMID39195339
PMCPMC11353039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.